Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

CFO of Dyne Therapeutics (since March 2025). EVP/CFO of Editas Medicine (2023-2025). CFO of AVEO Oncology (2020-2023). 15+ years in investment management covering healthcare and life sciences.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

SAB Biotherapeutics, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Dyne Therapeutics, Inc.

Open Dyne Therapeutics, Inc. profile →

Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-28

Dyne Therapeutics,…Dyne Therapeutics, Inc.SAB Biotherapeutic…SAB Biotherapeutics, Inc.Erick Lucera

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingDYN DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 2 · Sec FilingSABS 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 3 · Sec FilingSABS DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:erick-lucera
Record version
public-0

Published evidence records

6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. DYN DEF 14A executive officers

    sec filing · Source published: Apr 23, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Dyne Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Financial Officer and Treasurer · Claim reviewed: May 16, 2026

  2. Open source

    sec def 14a · Source published: Apr 23, 2026 · Retrieved: Sep 6, 2026

    Supports 1 claim
    • Professional Role: Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

  3. SABS 10-K executive officers

    sec filing · Source published: Mar 9, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at SAB Biotherapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Class I Director · Claim reviewed: May 16, 2026
    • Other Company Role: Erick Lucera is also linked to Dyne Therapeutics as Chief Financial Officer. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. SABS DEF 14A director slate

    sec filing · Source published: Aug 29, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  5. Open source

    sec proxy · Source published: Aug 29, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at SAB Biotherapeutics, Inc. · Claim reviewed: Sep 6, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of SAB Biotherapeutics, Inc. · Claim reviewed: Sep 6, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of SAB Biotherapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Dyne Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at SAB Biotherapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer and Treasurer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Class I Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedErick Lucera is also linked to Dyne Therapeutics as Chief Financial Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources6 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  2. https://www.sec.gov/Archives/edgar/data/1818794/000119312526173655/dyn-20260422.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: Chief Financial Officer and Treasurer at Dyne Therapeutics, Inc. (NASDAQ: DYN)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  5. https://www.sec.gov/Archives/edgar/data/1833214/000119312525192856/sabs_def14a_series_b_xxb.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at SAB Biotherapeutics, Inc. (NASDAQ: SABSW)

  6. https://www.sec.gov/Archives/edgar/data/1833214/000119312525192856/sabs_def14a_series_b_xxb.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership